Drug Development Technology-Updates The latest content updates from the www.drugdevelopment-technology.com web site http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ Drug Development Technology-Updates http://www.drugdevelopment-technology.com/content/images/logo_big.gif UCB and Dermira report positive Phase III trial results of Cimzia to treat chronic plaque psoriasis http://www.drugdevelopment-technology.com/news/newsucb-and-dermira-report-positive-phase-iii-cimpact-trial-results-of-cimzia-to-treat-chronic-plaque-psoriasis-5720215 http://www.drugdevelopment-technology.com/news/newsucb-and-dermira-report-positive-phase-iii-cimpact-trial-results-of-cimzia-to-treat-chronic-plaque-psoriasis-5720215 UCB and Dermira have reported positive results from its Phase III CIMPACT trial of Cimzia (certolizumab pegol) to treat adult patients with moderate-to-severe chronic plaque psoriasis. Fri, 20 Jan 2017 00:00:00 GMT M&As this week: Malin Corporation, Eli Lilly and Company http://www.drugdevelopment-technology.com/news/newsmas-this-week-malin-corporation-eli-lilly-and-company-5720788 http://www.drugdevelopment-technology.com/news/newsmas-this-week-malin-corporation-eli-lilly-and-company-5720788 Irish life sciences company Malin Corporation has acquired 33% stake in Wren Therapeutics with the aim of developing rational therapeutic strategies. Fri, 20 Jan 2017 00:00:00 GMT Deals this week: Takeda Pharmaceutical, HUYA Bioscience International, Egalet http://www.drugdevelopment-technology.com/news/newsdeals-this-week-takeda-pharmaceutical-huya-bioscience-international-egalet-5720871 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-takeda-pharmaceutical-huya-bioscience-international-egalet-5720871 Japanese pharmaceutical company Takeda Pharmaceutical has signed a global agreement with US-based bio-pharmaceutical company Ovid Therapeutics for clinical development and commercialisation of the former’s investigational new drug TAK-935. Fri, 20 Jan 2017 00:00:00 GMT Daiichi Sankyo begins Phase I/II trial of U3-1402 to treat breast cancer in Japan http://www.drugdevelopment-technology.com/news/newsdaiichi-sankyo-begins-phase-iii-trial-of-u3-1402-to-treat-breast-cancer-in-japan-5720107 http://www.drugdevelopment-technology.com/news/newsdaiichi-sankyo-begins-phase-iii-trial-of-u3-1402-to-treat-breast-cancer-in-japan-5720107 Japanese-based pharmaceutical company Daiichi Sankyo has begun its Phase I/II trial of U3-1402 to treat patients with HER3-positive metastatic or unresectable breast cancer in Japan. Fri, 20 Jan 2017 00:00:00 GMT Using FlexyCUBE in Risk and Quality Analysis http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/flexycube-risk-quality-analysis/ http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/flexycube-risk-quality-analysis/ In the first reaction step, an acid is added with constant thermal reduction (TR) control and stirrer speed. Thu, 19 Jan 2017 17:02:00 GMT Examples of 505(b)(2) Applications http://www.drugdevelopment-technology.com/contractors/regulatory-affairs/pharmaceutical-developmentgroup/pressexamples-of-505b2-applications.html http://www.drugdevelopment-technology.com/contractors/regulatory-affairs/pharmaceutical-developmentgroup/pressexamples-of-505b2-applications.html The 505(b)(2) consulting is a mainstay of PDG® activity. What are you doing to hedge against increasingly crowded traditional drug markets? Thu, 19 Jan 2017 13:10:00 GMT Pharmatest Services-Research Models to Evaluate Drug Candidate Efficacy http://www.drugdevelopment-technology.com/contractors/contract_research/pharmatest-services-pharma/ http://www.drugdevelopment-technology.com/contractors/contract_research/pharmatest-services-pharma/ Pharmatest Services offers preclinical research models designed to prove efficacy of drug candidates for oncology and skeletal diseases. Thu, 19 Jan 2017 00:00:00 GMT SWOG to conduct immunotherapy clinical trial to treat rare cancers http://www.drugdevelopment-technology.com/news/newsswog-to-conduct-immunotherapy-clinical-trial-to-treat-rare-cancers-5719617 http://www.drugdevelopment-technology.com/news/newsswog-to-conduct-immunotherapy-clinical-trial-to-treat-rare-cancers-5719617 SWOG, a part of National Cancer Institute’s National Clinical Trials Network and the NCI Community Oncology Research Programme, has launched the DART immunotherapy trial of ipilimumab and nivolumab (Opdivo) to treat rare cancers. Thu, 19 Jan 2017 00:00:00 GMT Rubraca (rucaparib) for the Treatment of Advanced Ovarian Cancer http://www.drugdevelopment-technology.com/projects/rubraca-rucaparib-for-the-treatment-of-advanced-ovarian-cancer/ http://www.drugdevelopment-technology.com/projects/rubraca-rucaparib-for-the-treatment-of-advanced-ovarian-cancer/ Poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor Rubraca™ (rucaparib) is indicated for the treatment of BRCA mutation-linked advanced ovarian cancer. Thu, 19 Jan 2017 00:00:00 GMT Interface Clinical Research suggests new model for primary care clinical trials in UK http://www.drugdevelopment-technology.com/news/newsinterface-clinical-research-suggests-new-model-for-primary-care-clinical-trials-in-uk-5719335 http://www.drugdevelopment-technology.com/news/newsinterface-clinical-research-suggests-new-model-for-primary-care-clinical-trials-in-uk-5719335 UK-based clinical trials company Interface Clinical Research has suggested a new model to conduct primary care clinical trials following their launch at the Royal Society in London. Thu, 19 Jan 2017 00:00:00 GMT Protagonist Therapeutics initiates Phase IIb trial of PTG-100 to treat ulcerative colitis http://www.drugdevelopment-technology.com/news/newsprotagonist-therapeutics-starts-phase-iib-trial-of-ptg-100-to-treat-ulcerative-colitis-5718807 http://www.drugdevelopment-technology.com/news/newsprotagonist-therapeutics-starts-phase-iib-trial-of-ptg-100-to-treat-ulcerative-colitis-5718807 US-based clinical-stage biopharmaceutical company Protagonist Therapeutics has initiated its Phase IIb clinical trial of PTG-100 to treat ulcerative colitis. Thu, 19 Jan 2017 00:00:00 GMT New clinical trial to test drug combination to treat osteogenesis imperfecta http://www.drugdevelopment-technology.com/news/newsnew-clinical-trial-to-test-drug-combination-to-treat-osteogenesis-imperfecta-5719102 http://www.drugdevelopment-technology.com/news/newsnew-clinical-trial-to-test-drug-combination-to-treat-osteogenesis-imperfecta-5719102 The University of Edinburgh will conduct a six-year trial of teriparatide and zoledronic acid combination to treat a condition called osteogenesis imperfecta (OI). Wed, 18 Jan 2017 00:00:00 GMT Jazz Pharmaceuticals begins enrolment in Phase III trial of defitelio to treat VOD http://www.drugdevelopment-technology.com/news/newsjazz-pharmaceuticals-starts-enrolment-in-phase-iii-trial-of-defitelio-to-treat-vod-5718642 http://www.drugdevelopment-technology.com/news/newsjazz-pharmaceuticals-starts-enrolment-in-phase-iii-trial-of-defitelio-to-treat-vod-5718642 Ireland-based Jazz Pharmaceuticals has started patient enrolment in a Phase III clinical trial of defitelio (defibrotide sodium) against best supportive care (BSC) to address hepatic veno-occlusive disease (VOD) in adult and pediatric patients underg… Wed, 18 Jan 2017 00:00:00 GMT Allergan and Gedeon Richter report positive results from Venus II trial of ulipristal acetate http://www.drugdevelopment-technology.com/news/newsallergan-and-gedeon-richter-report-positive-results-from-venus-ii-trial-of-ulipristal-acetate-5718106 http://www.drugdevelopment-technology.com/news/newsallergan-and-gedeon-richter-report-positive-results-from-venus-ii-trial-of-ulipristal-acetate-5718106 Allergan and Gedeon Richter have reported positive results from Venus II, the second of two pivotal phase III clinical trials evaluating the efficacy and safety of ulipristal acetate in women with abnormal bleeding due to uterine fibroids. Wed, 18 Jan 2017 00:00:00 GMT Measuring the zeta potential of planar surfaces with Zetasizer Nano http://www.drugdevelopment-technology.com/contractors/delivery/malvern-drug-development/pressmeasuring-zeta-potential-planar-surfaces--zetasizer-nano.html http://www.drugdevelopment-technology.com/contractors/delivery/malvern-drug-development/pressmeasuring-zeta-potential-planar-surfaces--zetasizer-nano.html Malvern has announced it will host a webinar to discuss how to measure zeta surface potential. Tue, 17 Jan 2017 14:57:00 GMT Using Mophologically Directed Raman Spectroscopy to Detect Counterfeit Drugs http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/using/ http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/using/ In drug formulation, precise components require careful blending and processing to create a final product that can be administered to deliver the required clinical dose. Tue, 17 Jan 2017 14:44:00 GMT Clinical study suggests efficacy of modafinil to improve memory in patients with depression http://www.drugdevelopment-technology.com/news/newsclinical-study-suggests-efficacy-of-modafinil-to-improve-memory-in-patients-with-depression-5717552 http://www.drugdevelopment-technology.com/news/newsclinical-study-suggests-efficacy-of-modafinil-to-improve-memory-in-patients-with-depression-5717552 A clinical study conducted by the University of Cambridge has suggested efficacy of the drug modafinil for improving memory in patients recovering from depression. Tue, 17 Jan 2017 00:00:00 GMT BioLineRx begins Phase IIa trial of BL-8040 combined with KEYTRUDA to treat metastatic pancreatic cancer http://www.drugdevelopment-technology.com/news/newsbiolinerx-starts-phase-iia-trial-of-bl-8040-combined-with-keytruda-to-treat-metastatic-pancreatic-cancer-5718315 http://www.drugdevelopment-technology.com/news/newsbiolinerx-starts-phase-iia-trial-of-bl-8040-combined-with-keytruda-to-treat-metastatic-pancreatic-cancer-5718315 Clinical-stage bio-pharmaceutical company BioLineRx has begun its second Phase 2a trial investigating BL-8040 in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, in patients suffering with metastatic pancreatic cancer. Tue, 17 Jan 2017 00:00:00 GMT Chi-Med initiates Phase II study of sulfatinib to treat second-line biliary tract cancer in China http://www.drugdevelopment-technology.com/news/newschi-med-starts-phase-ii-study-of-sulfatinib-to-treat-second-line-biliary-tract-cancer-in-china-5716904 http://www.drugdevelopment-technology.com/news/newschi-med-starts-phase-ii-study-of-sulfatinib-to-treat-second-line-biliary-tract-cancer-in-china-5716904 Hutchison China MediTech (Chi-Med) has initiated its Phase II study by administering the first dose of sulfatinib to treat second-line biliary tract cancer (BTC) patients in China. Tue, 17 Jan 2017 00:00:00 GMT Pluristem closes enrolment for Phase II trial of PLX-PAD cells to treat intermittent claudication http://www.drugdevelopment-technology.com/news/newspluristem-closes-enrollment-for-phase-ii-trial-of-plx-pad-cells-to-treat-intermittent-claudication-5716058 http://www.drugdevelopment-technology.com/news/newspluristem-closes-enrollment-for-phase-ii-trial-of-plx-pad-cells-to-treat-intermittent-claudication-5716058 Israeli-based drug development company Pluristem Therapeutics has closed enrolment for its Phase II trial of placental expanded (PLX-PAD) cells to treat intermittent claudication (IC), a peripheral artery disease (PAD). Mon, 16 Jan 2017 00:00:00 GMT